Drug profile · INN
albuterol
AIROMIR AUTOHALER
albuterol (AIROMIR AUTOHALER) is a beta-2 adrenergic receptor agonist. Associated with GlaxoSmithKline. Route of administration: inhalation. Current US regulatory status: approved.
Drug details — albuterol
- US status
- approved
- Class
- —
- Route
- INHALATION
- Patents
- 4
- Programs
- 27
- Data quality
- 0.89
Quick answer
albuterol (AIROMIR AUTOHALER) is a beta-2 adrenergic receptor agonist. Associated with GlaxoSmithKline. Route of administration: inhalation. Current US regulatory status: approved.
Key facts
Mechanism of action
Beta-2 adrenergic receptor agonist
Primary target: Beta-2 adrenergic receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12383516
Albuterol aerosol suspension formulation for oral inhalation with high amount of green propellant hydrofluoroolefin (HFO) and free of co-solvent
granted -
US 7488758
Levalbuterol hydrochloride polymorph B
granted -
US 7482489
Enantiomerically pure (R)-albuterol dibenzoyltartrate and protected analogs thereof
granted -
US 7465831
Levalbuterol hydrochloride Polymorph A
granted
Frequently asked questions
What is albuterol?
albuterol (AIROMIR AUTOHALER) is a beta-2 adrenergic receptor agonist. Associated with GlaxoSmithKline. Route of administration: inhalation. Current US regulatory status: approved.
What is the brand name for albuterol?
AIROMIR AUTOHALER is a marketed brand name for albuterol. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of albuterol?
albuterol has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.